EMA Greenlights Capvaxive: A Breakthrough Pneumococcal Vaccine for Adults
01 Feb 2025
In a significant step forward in the fight against pneumococcal diseases, the European Medicines Agency (EMA) has recommended the approval of Capvaxive, a 21-valent pneumococcal polysaccharide conjugate vaccine. Intended for use in adults aged 18 years or older, this vaccine is designed to prevent invasive diseases and pneumonia caused by...
Read More